Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Integra Lifesciences Holdings (IART) EBT Margin (2016 - 2025)

Historic EBT Margin for Integra Lifesciences Holdings (IART) over the last 17 years, with Q3 2025 value amounting to 1.7%.

  • Integra Lifesciences Holdings' EBT Margin rose 36500.0% to 1.7% in Q3 2025 from the same period last year, while for Sep 2025 it was 33.19%, marking a year-over-year decrease of 324300.0%. This contributed to the annual value of 1.13% for FY2024, which is 63900.0% down from last year.
  • Integra Lifesciences Holdings' EBT Margin amounted to 1.7% in Q3 2025, which was up 36500.0% from 127.75% recorded in Q2 2025.
  • In the past 5 years, Integra Lifesciences Holdings' EBT Margin registered a high of 18.68% during Q1 2021, and its lowest value of 127.75% during Q2 2025.
  • For the 5-year period, Integra Lifesciences Holdings' EBT Margin averaged around 0.57%, with its median value being 7.27% (2023).
  • Per our database at Business Quant, Integra Lifesciences Holdings' EBT Margin surged by 154600bps in 2021 and then crashed by -1241200bps in 2025.
  • Integra Lifesciences Holdings' EBT Margin (Quarter) stood at 12.77% in 2021, then increased by 26bps to 16.13% in 2022, then crashed by -55bps to 7.27% in 2023, then dropped by -30bps to 5.09% in 2024, then plummeted by -133bps to 1.7% in 2025.
  • Its EBT Margin was 1.7% in Q3 2025, compared to 127.75% in Q2 2025 and 7.85% in Q1 2025.